A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

November 30, 2026

Study Completion Date

December 31, 2026

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

LY3938577

Administered SC

DRUG

Degludec

Administered SC

Trial Locations (26)

1204

Instituto Centenario, CABA

2000

Instituto Médico Catamarca IMEC, Rosario

28401

Accellacare - Wilmington, Wilmington

29607

Tribe Clinical Research, LLC, Greenville

33024

Encore Medical Research, Hollywood

33331

Encore Medical Research - Weston, Weston

33761

Tampa Bay Medical Research, Clearwater

33805

Clinical Research of Central Florida, Lakeland

37620

Holston Medical Group, Bristol

50266

Iowa Diabetes and Endocrinology Research Center, West Des Moines

63110

Washington University School of Medicine, St Louis

73069

AMR Clinical, Norman

75149

Southern Endocrinology Associates, Mesquite

75230

Velocity Clinical Research, Dallas, Dallas

77040

Juno Research, Houston

78231

Consano Clinical Research, LLC, Shavano Park

78596

Texas Valley Clinical Research, Weslaco

78749

Texas Diabetes & Endocrinology, P.A., Austin

84790

Chrysalis Clinical Research, St. George

85712

Tucson Clinical Research Institute, Tucson

91978

Encompass Clinical Research, Spring Valley

92780

University Clinical Investigators, Inc., Tustin

C1119ACN

CIPREC, Buenos Aires

C1128AAF

Mautalen Salud e Investigación, Buenos Aires

C1405BUB

Consultorio de Investigación Clínica EMO SRL, Buenos Aires

C1425AGC

Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada, Buenos Aires

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY